India’s long-held status as the “pharmacy of the world” could be affected by US President Donald Trump’s plan to impose steep tariffs on imported drugs from 2028, threatening the low-cost, export-driven model that has made the country a vital supplier of generic medicines, analysts have warned. Late last month, Trump announced that the US would impose 100 per cent tariffs on generic medicines from August 2028 and increase them to 200 per cent after one year, signalling a major push to bring more...